Review article: proton pump inhibitors and bacterial ov

Alimentary Pharmacology and Therapeutics
23, 3-10
DOI: 10.1111/j.1365-2036.2006.02707.x

Citation Report

#	Article	IF	Citations
1	Peptic ulcer disease. Current Opinion in Gastroenterology, 2006, 22, 607-611.	1.0	8
3	Gastric juice - a natural-born killer. Alimentary Pharmacology and Therapeutics, 2006, 23, 1677-1678.	1.9	0
4	Achlorhydria is associated with gastric microbial overgrowth and development of cancer: Lessons learned from the gastrin knockout mouse. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 607-622.	0.6	29
5	Microbial Colonization of the Upper Gastrointestinal Tract in Patients with Barrett's Esophagus. Clinical Infectious Diseases, 2007, 45, 29-38.	2.9	196
7	Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. International Journal of Infectious Diseases, 2007, 11, 417-422.	1.5	22
8	Use of Acid-Suppressing Drugs and the Risk of Bacterial Gastroenteritis. Clinical Gastroenterology and Hepatology, 2007, 5, 1418-1423.	2.4	118
9	Association of proton-pump inhibitors with outcomes inClostridium difficilecolitis. American Journal of Health-System Pharmacy, 2007, 64, 2359-2363.	0.5	90
10	Vibrio cholerae O1â€‰El Tor cluster in Sydney linked to imported whitebait. Medical Journal of Australia, 2007, 187, 345-347.	0.8	39
11	Small bowel bacterial overgrowth in adults: A potential contributor to intestinal failure. Current Gastroenterology Reports, 2007, 9, 463-7.	1.1	38
12	Pharmacologic management of gastroesophageal reflux disease. Current GERD Reports, 2007, 1, 109-113.	0.1	0
13	Control of Gastric Acid Secretion in Health and Disease. Gastroenterology, 2008, 134, 1842-1860.	0.6	367
14	Do We Need Gastric Acid?. Digestion, 2008, 77, 184-197.	1.2	37
15	Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy. American Journal of Gastroenterology, 2008, 103, 2031-2035.	0.2	112
16	Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?. American Journal of Gastroenterology, 2008, 103, 2972-2976.	0.2	91
17	Proton Pump Inhibitor Use and Enteric Infections. American Journal of Gastroenterology, 2009, 104, S10-S16.	0.2	79
18	The Effect of Proton Pump Inhibitors on the Human Microbiota. Current Drug Metabolism, 2009, 10, 84-89.	0.7	119
19	Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 498-547.	0.9	638
20	Proton pump inhibitors: actions and reactions. Drug Discovery Today, 2009, 14, 647-660.	3.2	88

#	Article	IF	Citations
21	Acid Inhibition and Infections Outside the Gastrointestinal Tract. American Journal of Gastroenterology, 2009, 104, S17-S20.	0.2	33
22	P289 Association between the use of proton pump inhibitors and a Clostridium difficile-associated disease outbreak: a case control study. International Journal of Antimicrobial Agents, 2009, 34, S116.	1.1	0
23	3 H+/K+ ATPase Inhibitors in the Treatment of Acid-Related Disorders. Progress in Medicinal Chemistry, 2009, 47, 75-162.	4.1	19
24	Does PPI therapy predispose to Clostridium difficile infection?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 555-557.	8.2	25
25	Small Intestinal Bacterial Overgrowth in Gastroparesis. Journal of Clinical Gastroenterology, 2010, 44, e8-e13.	1.1	51
26	Proton Pump Inhibitors in the Management of GERD. Journal of Gastrointestinal Surgery, 2010, 14, S62-S66.	0.9	32
27	Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS. Digestive Diseases and Sciences, 2010, 55, 2302-2308.	1.1	30
28	Chronic Abdominal Pain in Children Is Associated with High Prevalence of Abnormal Microbial Fermentation. Digestive Diseases and Sciences, 2010, 55, 124-130.	1.1	31
29	Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?. BMC Gastroenterology, 2010, 10, 23.	0.8	63
30	Metaâ€analysis: proton pump inhibitor use and the risk of communityâ€acquired pneumonia. Alimentary Pharmacology and Therapeutics, 2010, 31, 1165-1177.	1.9	149
31	Safety of the long-term use of proton pump inhibitors. World Journal of Gastroenterology, 2010, 16, 2323.	1.4	241
32	Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole. Therapeutics and Clinical Risk Management, 2010, Volume 6, 531-537.	0.9	5
33	Association Between Use of Proton Pump Inhibitors and a Clostridium difficileâ€“ Associated Disease Outbreak: Caseâ€“Control Study. Canadian Journal of Hospital Pharmacy, 2010, 63, 31-7.	0.1	7
34	Efficacy of Three Different Dosages of Esomeprazole in the Long-Term Management of Reflux Disease: A Prospective, Randomized Study, Using the Wireless Bravo pH System. American Journal of Gastroenterology, 2010, 105, 308-313.	0.2	13
35	Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ: British Medical Journal, 2010, 340, c2608-c2608.	2.4	20
36	Human intestinal microbiota and healthy ageing. Ageing Research Reviews, 2010, 9, 107-116.	5.0	280
37	Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. Gastroenterology, 2011, 141, 1314-1322.e5.	0.6	387
38	Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner. European Journal of Internal Medicine, 2011, 22, 561-568.	1.0	18

#	Article	IF	Citations
39	Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation, 2011, 41, 380-386.	1.7	103
41	Health benefits of probiotics: are mixtures more effective than single strains?. European Journal of Nutrition, 2011, 50, 1-17.	1.8	360
42	Expression of Cckbr, Gast, Reg1α, Tgfb1 genes in rat pancreas upon long-term hypoacidity and with administration of multiprobiotic Â«SymbiterÂ® acidophilicÂ» concentrated. Biopolymers and Cell, 2012, 28, 461-467.	0.1	2
43	The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?. International Journal of Inflammation, 2012, 2012, 1-13.	0.9	121
44	Is Microscopic Colitis a Drug-induced Disease?. Journal of Clinical Gastroenterology, 2012, 46, 811-822.	1.1	54
45	Considerations for the Use of Proton-Pump Inhibitors in Older Adults. The Consultant Pharmacist, 2012, 27, 114-120.	0.4	20
46	Natural History of Pediatric Intestinal Failure: Initial Report from the Pediatric Intestinal Failure Consortium. Journal of Pediatrics, 2012, 161, 723-728.e2.	0.9	382
47	Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study. BMC Gastroenterology, 2012, 12, 121.	0.8	11
48	Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Medicine, 2012, 10, 57.	2.3	23
49	Proton pump inhibitor therapy predisposes to communityâ€acquired <scp>S</scp>treptococcus pneumoniae pneumonia. Alimentary Pharmacology and Therapeutics, 2012, 36, 941-949.	1.9	64
50	Bacterial Flora as a Cause or Treatment of Chronic Diarrhea. Gastroenterology Clinics of North America, 2012, 41, 581-602.	1.0	17
51	Clostridium difficile -Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. American Journal of Gastroenterology, 2012, 107, 1001-1010.	0.2	420
52	Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis. Clinical Gastroenterology and Hepatology, 2012, 10, 225-233.	2.4	183
53	Gastroesophageal Reflux Disease in Children and Adolescents. Paediatric Drugs, 2012, 14, 79-89.	1.3	19
54	Proton Pump Inhibitor Therapy Use Does Not Predispose to Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology, 2012, 107, 730-735.	0.2	96
55	Regulation of Gastric Acid Secretion. , 2012, , 1281-1309.		5
56	Stress Prophylaxis in Intensive Care Unit Patients and the Role of Enteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2012, 36, 721-731.	1.3	37
57	NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. British Journal of Pharmacology, 2012, 165, 67-74.	2.7	131

#	Article	IF	Citations
58	Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiology Ecology, 2012, 80, 624-636.	1.3	111
59	Over-Prescription of Acid-Suppressing Medications in Infants: How It Came About, Why Itâ€™s Wrong, and What to Do About It. Journal of Pediatrics, 2012, 160, 193-198.	0.9	69
60	Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Review of Clinical Pharmacology, 2013, 6, 443-451.	1.3	101
61	Helicobacter pylori and the gastric microbiota. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 39-45.	1.0	125
62	Polypharmacy of Osteoarthritis: The Perfect Intestinal Storm. Digestive Diseases and Sciences, 2013, 58, 3088-3093.	1.1	40
63	Barrett Esophagus and Risk of Esophageal Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 627.	3.8	240
64	Associations between medication use and functional gastrointestinal disorders: a populationâ€based study. Neurogastroenterology and Motility, 2013, 25, 413.	1.6	19
65	Clostridium difficileinfection in children: a comprehensive review. Current Medical Research and Opinion, 2013, 29, 967-984.	0.9	43
66	Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children. Journal of Pediatrics, 2013, 163, 686-691.	0.9	47
67	Probiotics and prebiotics and health in ageing populations. Maturitas, 2013, 75, 44-50.	1.0	157
68	Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World Journal of Gastroenterology, 2013, 19, 1861.	1.4	143
69	Letter by Wallace and Chan Regarding Article, â€œDrug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirinâ€. Circulation, 2013, 128, e190.	1.6	1
70	The role of the gastrointestinal microbiome inHelicobacter pyloripathogenesis. Gut Microbes, 2013, 4, 505-531.	4.3	178
71	Microbial biofilms and gastrointestinal diseases. Pathogens and Disease, 2013, 67, 25-38.	0.8	74
72	Unveiling the Intricacies of Helicobacter pylori-Induced Gastric Inflammation: T Helper Cells and Matrix Metalloproteinases at a Crossroad. , 2013, , .		4
73	Microbial Profile of the Stomach: Comparison between Normal Mucosa and Cancer Tissue in the Same Patient. Journal of Bacteriology and Virology, 2014, 44, 162.	0.0	18
74	Efficacy and Safety of Histamine-2 Receptor Antagonists. JAMA Pediatrics, 2014, 168, 947.	3.3	49
75	Does Barrett's Esophagus Regress after Surgery (or Proton Pump Inhibitors). Digestive Diseases, 2014, 32, 156-163.	0.8	17

#	Article	IF	Citations
76	Environmental and NSAID-Enteropathy: Dysbiosis as a Common Factor. Current Gastroenterology Reports, 2014, 16, 377.	1.1	17
77	Microbiota in the stomach: New insights. Journal of Digestive Diseases, 2014, 15, 54-61.	0.7	50
78	The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome. Clinics in Laboratory Medicine, 2014, 34, 771-785.	0.7	128
79	Pharmacologic Options in the Management of Upper Gastrointestinal Bleeding: Focus on the Elderly. Drugs and Aging, 2014, 31, 349-361.	1.3	6
80	NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Current Opinion in Pharmacology, 2014, 19, 11-16.	1.7	66
81	Use of proton pump inhibitors and subsequent risk of celiac disease. Digestive and Liver Disease, 2014, 46, 36-40.	0.4	53
82	Eosinophilic Esophagitis. Gastroenterology Clinics of North America, 2014, 43, 243-256.	1.0	48
84	Acid suppression therapy and allergic reactions. Allergo Journal, 2015, 24, 25-33.	0.1	2
85	Acid suppression therapy and allergic reactions. Allergo Journal International, 2015, 24, 303-311.	0.9	17
86	Proton pump inhibitors overuse: only inappropriate prescriptions or further iatrogenic damage?. Italian Journal of Medicine, 2015, 9, 217.	0.2	1
87	Gut Microbiota: A Modulator of Brain Plasticity and Cognitive Function in Ageing. Healthcare (Switzerland), 2015, 3, 898-916.	1.0	67
88	Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0128004.	1.1	246
89	Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015, 41, 459-473.	0.8	78
90	The Effect of Proton Pump Inhibitors on Barrettâ€™s Esophagus. Gastroenterology Clinics of North America, 2015, 44, 415-424.	1.0	20
91	The Escherichia coli Acid Stress Response and Its Significance for Pathogenesis. Advances in Applied Microbiology, 2015, 92, 49-88.	1.3	65
92	Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. Journal of Gastroenterology, 2015, 50, 1079-1086.	2.3	26
93	Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. Clinical and Translational Gastroenterology, 2015, 6, e89.	1.3	132
94	Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. American Journal of Physiology - Renal Physiology, 2015, 308, G994-G1003.	1.6	41

#	Article	IF	Citations
95	Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: A randomized clinical trial. Digestive and Liver Disease, 2015, 47, 273-279.	0.4	11
96	The stomach in health and disease. Gut, 2015, 64, 1650-1668.	6.1	283
97	Prebiotics and Probiotics in Aging Population. , 2016, , 693-705.		0
98	Analysis of Gastric Microbiota by Pyrosequencing: Minor Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis. Helicobacter, 2016, 21, 364-374.	1.6	92
99	Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Critical Care, 2016, 20, 120.	2.5	107
100	Microscopic Colitis. Inflammatory Bowel Diseases, 2016, 22, 450-458.	0.9	78
101	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Applied and Environmental Microbiology, 2016, 82, 6633-6644.	1.4	85
102	Eosinophilic Esophagitis: A Relevant Entity for the Otolaryngologist. Acta Otorrinolaringologica (English Edition), 2016, 67, 167-178.	0.1	2
103	The Effect of H. pylori Infection on the Gastric Microbiota. , 2016, , 529-533.		2
104	Esofagitis eosinofÃ¼ica: una entidad patolÃ³gica relevante para el otorrinolaringÃ³logo. Acta OtorrinolaringolÃ³gica EspaÃ±ola, 2016, 67, 167-178.	0.2	1
105	Mechanisms and therapeutic effectiveness of lactobacilli. Journal of Clinical Pathology, 2016, 69, 187-203.	1.0	195
106	Positive regulation of the enzymatic activity of gastric H + ,K + -ATPase by sialylation of its Î²-subunit. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1228-1235.	1.4	7
107	Reply to the letter by Kawada entitled â€˜â€˜Combined effect of proton-pump inhibitors and other drugs with regard to lower gastrointestinal tract bleeding with special reference to low-dose aspirinâ€™â€™. Journal of Gastroenterology, 2016, 51, 174-175.	2.3	1
108	Multistrain Probiotics. , 2016, , 279-302.		2
110	pH-independent immediate release polymethacrylate formulations â€“ an observational study. Drug Development and Industrial Pharmacy, 2016, 42, 578-583.	0.9	1
111	Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit. Clinical Gastroenterology and Hepatology, 2017, 15, 1030-1036.e1.	2.4	9
112	The Esophageal and Gastric Microbiome in Health and Disease. Gastroenterology Clinics of North America, 2017, 46, 121-141.	1.0	49
113	Impact of the Microbiota and Gastric Disease Development by Helicobacter pylori. Current Topics in Microbiology and Immunology, 2017, 400, 253-275.	0.7	66

#	Article	IF	Citations
114	GERD Management. American Journal of Lifestyle Medicine, 2017, 11, 24-28.	0.8	2
115	Mucosa-Related Gastropathology: The Upper Gastrointestinal Tract and the Microbiome. , 2017, , 1447-1462.		0
116	Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies. Scientific Reports, 2017, 7, 43946.	1.6	45
117	Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection. Clinical Infectious Diseases, 2017, 65, 1638-1643.	2.9	7
118	Clinical and surgical factors associated with organ/space surgical site infection after laparoscopic gastrectomy for gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 1667-1674.	1.3	19
119	Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan. Frontiers in Pharmacology, 2017, 8, 481.	1.6	29
120	Findings in exudates can help distinguish benign gastric ulcers from ulcerated adenocarcinomas. Histopathology, 2018, 73, 215-219.	1.6	2
121	Proton pump inhibitor medication is associated with colonisation of gut flora in the oropharynx. Acta Anaesthesiologica Scandinavica, 2018, 62, 791-800.	0.7	7
122	Modulatory activities of Chrysophyllum albidum and its fractions on microflora and colonic pump activities during inflammatory phase of colitis healing in experimental mice. Food Bioscience, 2018, 22, 38-49.	2.0	2
123	Speculation as to why the Frequency of Eosinophilic Esophagitis Is Increasing. Current Gastroenterology Reports, 2018, 20, 26.	1.1	17
124	Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. Journal of Neurogastroenterology and Motility, 2018, 24, 182-196.	0.8	155
125	Omeprazole Minimally Alters the Fecal Microbial Community in Six Cats: A Pilot Study. Frontiers in Veterinary Science, 2018, 5, 79.	0.9	15
126	Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. BMC Gastroenterology, 2018, 18, 20.	0.8	22
127	Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2019, 84, 44-51.	0.1	2
128	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. Journal of Gastroenterology, 2019, 54, 837-844.	2.3	15
129	Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and metaâ€analysis of randomized controlled trials and observational studies. Expert Opinion on Drug Safety, 2019, 18, 163-172.	1.0	44
130	Gastroesophageal Reflux in the Child with Cerebral Palsy. , 2019, , 1-15.		0
131	Microbiota and gastrointestinal cancer. Journal of the Formosan Medical Association, 2019, 118, S32-S41.	0.8	61

#	Article	IF	Citations
133	Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose. Nitric Oxide - Biology and Chemistry, 2019, 89, 54-63.	1.2	49
134	The relationship between gastric microbiota and gastric disease. Scandinavian Journal of Gastroenterology, 2019, 54, 391-396.	0.6	32
135	Impact factors that modulate gastric cancer risk inHelicobacter pyloriâ€infected rodent models. Helicobacter, 2019, 24, e12580.	1.6	9
136	The Gastric Microbiome in Benign and Malignant Diseases. , 2019, , 101-108.		1
137	Gastric Microbiota: Between Health and Disease. , 0, , .		0
138	Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins, 2019, 11, 677.	1.5	137
139	Helicobacter pylori antibody and pepsinogen testing for predicting gastric microbiome abundance. PLoS ONE, 2019, 14, e0225961.	1.1	4
140	Systemic sclerosis. , 2019, , 291-329.		0
141	Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter, 2019, 24, e12547.	1.6	67
142	Novel Implementation of Genotypeâ€Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. Clinical and Translational Science, 2019, 12, 172-179.	1.5	22
143	SÃntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicÃ©ntrica en MÃ©xico. Revista De GastroenterologÃa De MÃ©xico, 2019, 84, 44-51.	0.4	9
144	Bacterial colonization of the stomach and duodenum in a Swedish population with and without proton pump inhibitor treatment. JGH Open, 2020, 4, 405-409.	0.7	6
145	The Role of Gastric Mucosal Immunity in Gastric Diseases. Journal of Immunology Research, 2020, 2020, 1-8.	0.9	23
146	Early Life Risk Factors in Pediatric EoE: Could We Prevent This Modern Disease?. Frontiers in Pediatrics, 2020, 8, 263.	0.9	20
147	Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide registerâ€based pathology cohort. Neurogastroenterology and Motility, 2021, 33, e14072.	1.6	30
149	The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis. , 2022, , 442-454.		0
150	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nature Communications, 2021, 12, 1926.	5.8	22
151	A Rare Case of Delayed Perigastric Abscess after Curative Resection of Early Gastric Cancer by Uncomplicated Endoscopic Submucosal Dissection: Successful Treatment with Endoscopic Ultrasound-guided Drainage. Internal Medicine, 2021, 60, 1383-1387.	0.3	5

#	Article	IF	Citations
152	Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. Surgical Clinics of North America, 2021, 101, 391-403.	0.5	1
153	Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling. Gastric Cancer, 2021, 24, 1242-1253.	2.7	26
154	Association between proton pump inhibitors and periodontal disease severity. Clinical and Experimental Dental Research, 2022, 8, 395-401.	0.8	6
156	Systemic Sclerosis. , 2013, , 955-969.		1
157	Gastric Secretion. , 2010, , 817-832.e7.		3
158	Septic course of chronic pancreatitis caused by infected visceral pseudoaneurysm content. Vasa - European Journal of Vascular Medicine, 2008, 37, 379-382.	0.6	3
159	Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. International Journal for Quality in Health Care, 2020, 32, 292-299.	0.9	21
160	Inflammation, atrophy, and gastric cancer. Journal of Clinical Investigation, 2007, 117, 60-69.	3.9	661
161	Probiotics and Prebiotics in Elderly Individuals. , 2009, , .		12
162	Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis. PLoS ONE, 2016, 11, e0168618.	1.1	21
163	Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine Research, 2015, 7, 880-883.	0.6	12
164	Influence of oxidative stress on the level of genes expression TGFB1 and HGF in rat liver upon long-term gastric hypochlorhydria and administration of multiprobiotic Symbiter. Ukrainian Biochemical Journal, 2013, 85, 114-123.	0.1	12
165	Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: A retrospective study of 932 patients. World Journal of Gastroenterology, 2015, 21, 4574-4582.	1.4	20
166	Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract. Gut and Liver, 2020, 14, 179-189.	1.4	28
167	Atrophy and Altered Mesenchymalâ€"Epithelial Signaling Preceding Gastric Cancer. , 2009, , 449-482.		1
168	Acid Inhibition and Infections Outside the Gastrointestinal Tract. American Journal of Gastroenterology, 2009, 104, S17-S20.	0.2	0
169	Proton Pump Inhibitor Use and Enteric Infections. American Journal of Gastroenterology, 2009, 104, S10-S16.	0.2	0
170	Bacterial Overgrowth. , 2010, , 189-207.		1

#	Article	IF	Citations
171	A Case of Collagenous Colitis Causing Alimentary Canal Puncture. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2013, 74, 3082-3086.	0.0	0
172	Changes of energy balance of rat liver and pancreas upon gastric hypoacidity and search of approaches for its recovery. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2014, 68, 54-57.	0.1	0
173	Microflora of upper gastrointestinal tract in gastric cancer patients. Korean Journal of Clinical Oncology, 2015, 11, 87-94.	0.1	0
174	Which Gastric Microbiota Associated with <i>H. pylori</i> in Dyspeptic Patients with Gastritis. Open Journal of Gastroenterology, 2018, 08, 425-433.	0.1	1
175	Bacteriologic Evaluation of Ventilator-Associated Pneumonia According to Stress Related Mucosal Disease Prophylaxis in the Intensive Care Unit. Archives of Clinical Infectious Diseases, 2018, 13, .	0.1	0
176	Antioxidant protection enzyme activity in the blood serum and large intestinal mucosa of rats with prolonged gastric hypochlorhydria and given multiprobiotics. Regulatory Mechanisms in Biosystems, 2020, 10, 438-444.	0.5	0
177	Gastroesophageal Reflux in the Child with Cerebral Palsy. , 2020, , 751-765.		0
179	Bakterielle Ãœberbesiedlung. , 2006, , 277-285.		0
180	The bacterial association with oral cavity and intra-abdominal abscess after gastrectomy. PLoS ONE, 2020, 15, e0242091.	1.1	5
181	The impact of acid-suppressing drugs to the patients with chronic obstructive pulmonary disease: A nationwide, population-based, cohort study. Journal of Research in Medical Sciences, 2015, 20, 263-7.	0.4	7
182	Association Between Proton Pump Inhibitor Exposure and Infection in Elderly, Hospitalized Patients. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 21-25.	0.6	0
183	The role of non- bacteria in the development of gastric cancer. American Journal of Cancer Research, 2020, 10, 2271-2281.	1.4	3
185	Complex Interplay of Heme-Copper Oxidases with Nitrite and Nitric Oxide. International Journal of Molecular Sciences, 2022, 23, 979.	1.8	6
187	Antibiotic and antifungal use in pediatric leukemia and lymphoma patients are associated with increasing opportunistic pathogens and decreasing bacteria responsible for activities that enhance colonic defense. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	6
188	Use of digital pathology and artificial intelligence for the diagnosis of Helicobacter pylori in gastric biopsies. Pathologica, 2022, 114, 295-303.	1.3	7
189	Proton pump inhibitor usage associates with higher risk of first episodes of pneumonia and peritonitis in peritoneal dialysis patients. Renal Failure, 2022, 44, 1623-1631.	0.8	2
190	Proton pump inhibitors: Are they safe?. Gastroenterology & Hepatology (Bartlesville, Okla), 2022, 13, 34-47.	0.0	1
191	Oral omeprazole and diclofenac intake is associated with increased faecal calprotectin levels: a randomised open-label clinical trial. European Journal of Gastroenterology and Hepatology, 2023, 35, 52-58.	0.8	1

#	Article	IF	Citations
192	Crosstalk between Helicobacter pylori and gastrointestinal microbiota in various gastroduodenal diseasesâ€"A systematic review. 3 Biotech, 2023, 13, .	1.1	1
196	The Effect of H. pylori Infection on the Gastric Microbiota. , 2023, , 701-723.		0